John Wentworth is an endocrinologist and diabetes researcher at the Royal Melbourne Hospital and the Walter and Eliza Hall Institute. With Peter Colman and Michelle So, he leads Type1Screen, a national platform offering screening for type 1 diabetes risk and support for those who test positive. He is part of the multinational TrialNet consortium that in June 2022 announced results of a clinical trial demonstrating that immune therapy can delay the onset of type 1 diabetes. He currently leads the Australiasian T1D Immunotherapy Collaborative that aims to accelerate development of T1D prevention through increased clinical trial activity throughout Australia.

Michelle So is a Clinical Research Fellow at St Vincent’s Institute and endocrinologist at Royal Melbourne and Northern Hospitals. She obtained her PhD in 2018 investigating C-peptide as a target of peripheral T-cells in type 1 diabetes. Michelle completed post-doctoral research in the area of type 1 diabetes prevention and translational immunology at the Diabetes Clinical Research Program at Benaroya Research Institute (Seattle, USA) in 2019-2020. Michelle is the education and training lead for the Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC).

Alison Roberts is a clinical nurse with more than 15 years' experience in clinical research, including coordinating clinical trials, and screening and monitoring studies of individuals at risk of developing type 1 diabetes. Alison has a particular interest in understanding the psychosocial aspects of managing type 1 diabetes and research.

Jenny Couper is a paediatric endocrinologist and head of paediatrics, University of Adelaide. She has lead the Environmental Determinants of Islet Autoimmunity (ENDIA) nation-wide consortium since 2012. Over 10 years this consortium has reached full recruitment of 1500 babies. She is a steering member of two related initiatives in the prevention of type 1 diabetes space: the JDRFA Australian Population Screening program pilot for type 1 diabetes and the JDRFA Australasian Immune trials Collaborative. She was elected a member of the International Society of Pediatric and Adolescent Diabetes (ISPAD) Advisory Council in 2020.

Meaghan Read is the Community Engagement Lead at Diabetes Victoria, a member of the ACADI co-design platform and the Chair of the Community Engagement Panel for the Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC). Meaghan brings 37 years of lived experience of type 1 diabetes along with professional experience in laboratory, clinical and pharmaceutical research to these roles. She holds a BSc(Hons) from The University of Melbourne together with qualifications in Diabetes Education and Community Engagement. Meaghan is a passionate diabetes advocate with great passion for community engagement and co-design in the research sector.